DE68924979T2 - Nachweis der expression von neu genen und produkten. - Google Patents

Nachweis der expression von neu genen und produkten.

Info

Publication number
DE68924979T2
DE68924979T2 DE68924979T DE68924979T DE68924979T2 DE 68924979 T2 DE68924979 T2 DE 68924979T2 DE 68924979 T DE68924979 T DE 68924979T DE 68924979 T DE68924979 T DE 68924979T DE 68924979 T2 DE68924979 T2 DE 68924979T2
Authority
DE
Germany
Prior art keywords
oncogenes
neu
expression
products
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68924979T
Other languages
English (en)
Other versions
DE68924979D1 (de
Inventor
A Weinberg
P Mazzara
H Morgan
J Mckenzie
J Marks
Walter P Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Oncogene Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogene Science Inc filed Critical Oncogene Science Inc
Publication of DE68924979D1 publication Critical patent/DE68924979D1/de
Application granted granted Critical
Publication of DE68924979T2 publication Critical patent/DE68924979T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE68924979T 1988-04-18 1989-04-18 Nachweis der expression von neu genen und produkten. Expired - Lifetime DE68924979T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18250188A 1988-04-18 1988-04-18
US29718889A 1989-01-13 1989-01-13
PCT/US1989/001636 WO1989010412A1 (en) 1988-04-18 1989-04-18 Detection of neu gene expression and products

Publications (2)

Publication Number Publication Date
DE68924979D1 DE68924979D1 (de) 1996-01-11
DE68924979T2 true DE68924979T2 (de) 1996-10-24

Family

ID=26878143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924979T Expired - Lifetime DE68924979T2 (de) 1988-04-18 1989-04-18 Nachweis der expression von neu genen und produkten.

Country Status (8)

Country Link
EP (1) EP0412116B1 (de)
JP (3) JPH03505964A (de)
KR (1) KR900700625A (de)
AT (1) ATE130873T1 (de)
AU (1) AU3568289A (de)
CA (1) CA1341191C (de)
DE (1) DE68924979T2 (de)
WO (1) WO1989010412A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DK0474727T3 (da) * 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
DE68926248T2 (de) * 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
AU4025193A (en) * 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1994000764A1 (en) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6709858B1 (en) 1997-11-03 2004-03-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US7098191B2 (en) 1997-11-03 2006-08-29 The Arizona Board Of Reagents Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
DE60329020D1 (de) 2002-03-01 2009-10-08 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
JP5981853B2 (ja) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
CA1252046A (en) * 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection

Also Published As

Publication number Publication date
EP0412116B1 (de) 1995-11-29
DE68924979D1 (de) 1996-01-11
KR900700625A (ko) 1990-08-16
CA1341191C (en) 2001-02-27
JP2000175692A (ja) 2000-06-27
WO1989010412A1 (en) 1989-11-02
AU3568289A (en) 1989-11-24
EP0412116A1 (de) 1991-02-13
ATE130873T1 (de) 1995-12-15
JP2004043486A (ja) 2004-02-12
JPH03505964A (ja) 1991-12-26

Similar Documents

Publication Publication Date Title
DE68924979D1 (de) Nachweis der expression von neu genen und produkten.
WO1987007646A3 (en) Detection of point mutations in neu genes
Rachkovsky et al. Melanoma× macrophage hybrids with enhanced metastatic potential
ES8606903A1 (es) Un metodo para entregar un agente seleccionado a un lugar biologico caracterizado por la presencia de una secuencia de adn seleccionada.
ES8609473A1 (es) Un metodo para detectar material genetico objetivo
DE69528653D1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
IL84866A0 (en) Method for detecting tumors
FI875082A (fi) Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner.
NO893583D0 (no) Amplifikasjon og paavisning av nukleinsyresekvenser.
DE69940969D1 (de) Detektion von neoplasien durch speichelanalyse
Kolodner et al. Gene 4 protein of bacteriophage T7. Purification physical properties, and stimulation of T7 DNA polymerase during the elongation of polynucleotide chains.
DE69120936D1 (de) Genetischer test für zytochrom-p450
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
ATE125872T1 (de) Nachweis von campylobacter.
CN105525010A (zh) 一种茎环结构组合探针及其应用
Heard et al. Electrophoretic mobility of cultured mesodermal tissue cells
EP0128018A3 (en) Molecular genetic probe, and method of forming same, assay technique and kit using said molecular genetic probe
ATE139260T1 (de) Diagnostische gene zum nachweis von toxoplasmose
Nash Purification of Bacteriophage λ, Int Protein
ATE429517T1 (de) Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom
DE69734595D1 (de) Verfahren zum entdecken von telomerase-aktivität
ATE293707T1 (de) Nukelinsäure primer und proben zum nachweis von tumorzellen
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
Ohno et al. Antigenic relatedness of the DNA polymerase of human breast cancer particles to the enzyme of the Mason-Pfizer monkey virus.
Viola et al. Differences in murine leukaemia virus-specific DNA sequences in normal and malignant cells

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ONCOGENE SCIENCE, INC., UNIONDALE, N.Y., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: OSI PHARMACEUTICALS,INC.(N.D.GES.D.STAATES DELAWAR